Arvee Laboratories (India)
- Market cap
- ₹ 201 Cr.
- P/E
- 51x
- P/B
- 6.44x
- 52-week range
- 129.11 – 290.78
- ROE
- 8%
- ROCE
- 7.9%
- Dividend yield
- 0%
- Debt / equity
- 0.03
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- NSE
About
Arvee Laboratories (India) Limited is an India-based company. The Company is engaged in manufacturing of specialized chemicals. It operates through Textile and Non-Textile segments. It offers polymer modifiers, contrast media intermediates, and drug intermediates. Its polumer modifier products include Dimethyl 5-Sodiosulfoisophthalate, 5-Sulfoisophthalic Acid Mono Sodium Salt, 5-Sulfoisophthalic Acid Mono Lithium Salt, and 5-Sodiosulfo-Bis-Isophthalate. Its contrast media intermediate products include 5-Nitroisophthalic acid, Dimethyl 5-Nitroisophthalate, Monomethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Aminoisophthalate, 3,5-Dinitrobenzoic Acid, and 3,5-Diamino Benzoic Acid. Its drug intermediates include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine, and 2-Chloro-5-Nitrobenzoic Acid.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Arvee Laboratories (India) against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)51 against a typical 25.8: pricier than most peers (1st = cheapest).97th of 129
- Sales growth+130.3% against a typical +25.9% from a year earlier.7th of 112
- Profit growth+894.1% against a typical +42.4% from a year earlier.6th of 102
- Share price, 3 months+18.8% against a typical −5.8%.19th of 118
- Size₹ 200.6 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).76th of 126
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
No up-to-date rating
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil B-(Issuer Not Cooperating) | Stable | 27 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 27 Feb 2026 | Reaffirmed | Crisil B-(Issuer Not Cooperating) | — | CRISIL | ₹ 14 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 7 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 19 May 2026 | Financial Results/Other business matters | ARVEE : 19-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 18, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 19, 2026, To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 18 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 13 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results/Other business matters | ARVEE : 14-Nov-2025 : The Company has informed the Exchange that a Board meeting to be held on November 13, 2025 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 14, 2025, To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 13 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 8 | 6 | 11 | 13 | 9 | 6 | 7 | 3 | 10 | 11 | 17 |
| Expenses | 8 | 7 | 5 | 9 | 11 | 9 | 6 | 7 | 3 | 8 | 10 | 15 |
| Operating Profit | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 2 |
| OPM % | 7.7% | 6.9% | 12.9% | 14.5% | 12% | 3.8% | 3.4% | 4.6% | 3.5% | 16.7% | 10.2% | 14.5% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Tax % | 25% | 25% | 81% | 25.4% | 25.2% | 25% | 22.2% | 5.6% | 0% | −30.7% | 38.4% | 26.2% |
| Net Profit | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 2 |
| EPS in Rs | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 | 0.01 | 1.66 | 0.47 | 1.53 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 2%
- 5 Years
- −8%
- 3 Years
- −20%
- TTM
- 17%
- 10 Years
- 30%
- 5 Years
- 0%
- 3 Years
- −15%
- TTM
- 196%
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 18%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Arvee Laboratories (India) | ₹ 187.50 | ₹ 201 Cr. | 51x | 6.4x | 8% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 102.6x | 27.4x | 31.4% | 17.7% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.5x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 108.7x | 14x | 13.6% | 21.7% |
Management
- Maulesh Hasmukhlal Raval
- Chief Financial Officer
- Neelam Dilip Chotrani
- Company Secretary & Compliance Officer
- Shalin Sudhakarbhai Patel
- Managing Director, Director
Prices are delayed and for information only. Nothing on this page is investment advice.